Japan: HMDMA sold as MBDB (Methyl-J)

[enquirewithin]

Identification of N-methyl-4-(3,4-methylenedioxyphenyl)butan-2-amine, distributed as MBDB

Teruki Matsumoto, Ruri Kikura-Hanajiri, Hiroyuki Kamakura, Nobuo Kawahara, Yukihiro Goda

National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya, Tokyo 158-8501, Japan

N-methyl-1-(3,4-methylenedioxyphenyl)butan-2-amine (MDP-2-MB, MBDB) is a new homologue of N-methyl-1-(3,4-methylenedioxyphenyl)propan-2-amine (MDMA), which is strictly controlled as a narcotic. As part of our continuous survey on illegal designer drugs in the Japanese market, we found that N-methyl-4-(3,4-methylenedioxyphenyl)butan-2-amine (MDP-3-MB, HMDMA) was being sold as MBDB. As this is the first time that HMDMA has been revealed to be in market distribution, and its physico-chemical data is thus far unreported, we describe the structure elucidation of HMDMA and comparative analysis with related compounds....

As far as we know, this is the first time that HMDMA has been shown to be in market distribution, although several reports have described its pharmacological activity and analytical methods.
Little is known about the hallucinogenic activity of HMDMA, but some qualitative differences in pharmacological activity have been observed. Davis and Borne2) have compared the acute toxicities of MDA and MDMA with those of 4-(3,4-methylenedioxyphenyl)butan-2-amine (HMDA) and HMDMA....


http://www.drugs-forum.com/forum/loc...tid=18&id=3090

[enquirewithin]

This is not likely to affect anyone outside Japan, but it is curious. It's a shame that the article casts no light on the effects on HDMA in humans.